Clinical Report: The Changing Economics of Retina

Overview

An analysis of Medicare data from 2000 to 2021 reveals a sixfold increase in vitreoretinal procedure volume, alongside a 32% decline in inflation-adjusted reimbursement. Notably, intravitreal injections saw a dramatic rise in volume, while many procedures experienced significant reimbursement cuts.

Background

Understanding the economics of retina care is crucial as it directly impacts the sustainability of practices and access to care. The rising volume of procedures juxtaposed with declining reimbursements raises concerns about the viability of providing high-quality retinal care.

Data Highlights

Key Findings

• The volume of vitreoretinal procedures increased sixfold from 2000 to 2021.
• Inflation-adjusted reimbursement for these procedures declined by an average of 32% over the same period.
• Intravitreal injections rose from 2,922 procedures in 2000 to 3,444,500 in 2021.
• Twenty of the 38 procedures analyzed showed statistically significant decreases in volume.
• Panretinal photocoagulation reimbursement declined by 73%, while cryotherapy for retinopathy decreased by 69%.
• The cumulative inflation-adjusted reimbursement for vitreoretinal procedures dropped from $742 million in 2010 to $514 million in 2021.

Clinical Implications

The significant decline in reimbursement may affect the financial sustainability of vitreoretinal practices. Clinicians should be aware of the changing treatment patterns and consider the economic implications when planning patient care.

Conclusion

The findings underscore the need for ongoing evaluation of the economic landscape in retina care to ensure access and sustainability in the face of rising procedure volumes and declining reimbursements.

Related Resources & Content

1. Hwang MW, Bommakanti N, Young BK, Besirli CG, J Vitreoretin Dis, 2024 -- Time-driven activity-based cost analysis of pars plana vitrectomy in rhegmatogenous retinal detachment at a large academic center.
2. Retinal Physician — The Changing Economics of Retina Recommendations
3. retinal physician — The Past, Present, and Future of Private Equity in Retina
4. retinal physician — UPFRONT: The New Career Landscape of Retina
5. retinal physician — Independently Owned, Consolidation, and Private Equity for Retina Practices
6. The Changing Economics of Retina Recommendations
7. The Past, Present, and Future of Private Equity in Retina
8. UPFRONT: The New Career Landscape of Retina
9. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
10. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - PubMed
11. Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol - PMC